Cancer BiologybioRxivPreprint
Targeted anti-BCR-ABL+ ALL therapy may benefit the heart
H. Kirchhoff, M. Ricke-Hoch, K. Wohlan…·D. Hilfiker-Kleiner
This paper shows that targeted therapies for BCR-ABL+ ALL can cause heart damage, but some treatments like dasatinib and venetoclax can reverse cardiac defects while others cannot.
DOI 10.1101/2021.06.04.447070